Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the significance of the RESORCE trial, which explored regorafenib (Stivarga) versus best supportive care for patients with unresectable hepatocellular carcinoma (HCC) who progressed after receiving sorafenib (Nexavar).

The RESORCE study is important for the HCC field because it demonstrates that patients have a promising option in the second-line treatment setting, Abou-Alfa explains.

This trial shows encouraging findings compared with prior studies, in which the placebo arms performed better in experimental arms, he adds.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

ASCO Annual Meeting

Conference

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the significance of the RESORCE trial, which explored regorafenib (Stivarga) versus best supportive care for patients with unresectable hepatocellular carcinoma who progressed after receiving sorafenib (Nexavar).

Dr. Abou-Alfa on Significance of RESORCE Trial for HCC